Adrian Bot

Cell & Gene Therapy Insights 2026; 12(1), 87–92 DOI: 10.18609/cgti.2026.011 In vivo CAR therapies are rapidly emerging as a strategy to address the scalability, access, and toxicity limitations associated with conventional ex vivo CAR-T cell products. This article reviews viral and LNP–RNA platform technologies, emerging clinical evidence, and key safety and regulatory considerations relative to established CAR-T and immune cell engager approaches.

Cell & Gene Therapy Insights 2023; 9(5), 709–717 DOI: 10.18609/cgti.2023.089 Adrian Bot Please enter your email to access content Please note all fields marked with an * are mandatory Title* Country* Please select which journals you are interested in: Cell and Gene Therapy Insights Immuno-Oncology Insights Vaccine Insights Please select your areas of interest: Drug Delivery Public Health Bioanalytics Manufacturing Vectors Analytical/QA/QC/CMC Business Development/Licensing/Finance Regulatory...

The quality and magnitude of host immune responses do not rely on the genetic background alone, but also depend on several cis- and trans-regulatory factors, epigenetic modifications of genomic DNA and histones influencing transcription and translation.